Roche pulls out of fibrosis alliance with Galapagos

11 March 2013

Belgium-based Galapagos (Euronext Brussels: GLPG) revealed that Swiss drug major Roche (ROG: SIX) has ended its alliance with the company in fibrosis. Roche will make a payment of 5.75 million euros ($7.5 million) to Galapagos for work completed in 2012, contributing to 2012 group revenues.

With the ending of the deal, Galapagos has regained the worldwide rights to all fibrosis assays and the targets discovered in the alliance. These novel targets were identified in various unique human primary cell assays mimicking fibrosis. Galapagos will have received a total of 16 million euros in upfront and milestone payments, including this latest payment. The original agreement for chronic obstructive pulmonary disease (COPD) was signed in December 2009 and broadened to fibrosis in December 2010.

Will seek new partner

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK